In this study, we assessed the effect of vitamin C on elimination of the unexplained hyperferritinemia on EPO-hyporesponsive anemia in hemodialysis patients without changing the starting maintenance dosage of rEPO. In a crossed over, single blind randomized controlled trial, thirty HD patients who met the eligibility criteria, patients were randomly assigned into one of following groups. The patients in the intervention group received standard care and adjuvant therapy of 500 mg of intravenous vitamin C (IVAA) along with each dialysis session at the first week of each month (total 1500 mg/month) for three months and in the control group received standard cares only. Then, the patients passed two months wash out period and then they were crossed over for another three months. Hemoglobin, mean corpuscular volume, serum iron, iron-binding capacity, ferritin level, and TSAT were assessed every month. In addition, biointact parathyroid hormone, liver enzymes, albumin, and cholesterol were measured every 3 months.